Table 5. . FDA-approved indications for canagliflozin.
| Year of label expansion | Indication |
|---|---|
| 2013 | Adjunct to diet and exercise to improve glycemic control in adults with T2DM |
| 2018 | To reduce risk of major adverse CV events in adults with T2DM and established CV disease |
| 2019 | To reduce risk of end-stage kidney disease, worsening kidney function, CV death and hospitalization for heart failure in patients with T2DM and albuminuric kidney disease |
CV: Cardiovascular; T2DM: Type 2 diabetes mellitus.